Biora Therapeutics (NASDAQ:BIOR – Get Free Report) is anticipated to release its earnings data after the market closes on Tuesday, March 25th. Analysts expect Biora Therapeutics to post earnings of ($3.30) per share and revenue of $0.23 million for the quarter.
Biora Therapeutics Price Performance
Shares of NASDAQ:BIOR opened at $0.16 on Tuesday. The business’s 50 day simple moving average is $0.15 and its 200 day simple moving average is $2.25. Biora Therapeutics has a 1 year low of $0.15 and a 1 year high of $13.30. The company has a market capitalization of $723,680.00, a P/E ratio of -0.01 and a beta of 1.12.
Analyst Upgrades and Downgrades
Separately, HC Wainwright raised their price target on Biora Therapeutics from $15.00 to $23.00 and gave the stock a “buy” rating in a research report on Monday, November 18th.
About Biora Therapeutics
Biora Therapeutics, Inc, a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases.
Read More
- Five stocks we like better than Biora Therapeutics
- How to find penny stocks to invest and trade
- Can TikTok Stock Picks Really Make You Rich?
- High Dividend REITs: Are They an Ideal Way to Diversify?
- The “Quality” Rotation: Back to Basics Investing
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Biora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
